Rifampin-free Regimen Versus Rifampin-containing Regimen in the Treatment of Staphylococcal Prosthetic Valve Endocarditis

The primary objective of this study is to demonstrate that a rifampin-free regimen is non-inferior to the rifampin-containing regimen in terms of all-cause mortality in staphylococcal prosthetic valve endocarditis within 6 months after randomization.

NCT Number	NCT07345325
Lead Sponsor	Nantes University Hospital
Conditions	Infective Endocarditis
Enrollment	422 participants
Start Date	2026-06-11
Primary Completion	2030-12-11 (estimated)
Study Completion	2031-06-11 (estimated)
Updated on ClinicalTrials.gov	2026-07-28